Organic compounds -- part of the class 532-570 series – Organic compounds – Nitrogen attached directly or indirectly to the purine ring...
Reexamination Certificate
2006-05-05
2009-12-22
Wilson, James O (Department: 1624)
Organic compounds -- part of the class 532-570 series
Organic compounds
Nitrogen attached directly or indirectly to the purine ring...
C544S354000, C544S356000, C514S249000
Reexamination Certificate
active
07635775
ABSTRACT:
Disclosed are sulfonylquinoxalone acetamide derivatives useful as bradykinin antagonists.
REFERENCES:
patent: 3635971 (1972-01-01), Yellin et al.
patent: 3654275 (1972-04-01), McManus
patent: 5968951 (1999-10-01), Dodey et al.
patent: 6211196 (2001-04-01), Heitsch et al.
patent: 6369057 (2002-04-01), Billhardt et al.
patent: 7056937 (2006-06-01), Grant et al.
patent: 7183281 (2007-02-01), Grant et al.
patent: 43 41 663 (1993-12-01), None
patent: 0 622 361 (1994-11-01), None
patent: 1 188 755 (2002-03-01), None
patent: 03/007958 (2003-01-01), None
Kolos et al, Zhurnal Organichnoi ta Farmatsevtichnoi Khimii, vol. 1(1-2), pp. 31-34 (2003), as abstracted by STN, in the online database “CAPLUS.”
S.B. Wagh, et al., “Reactions of Cyclic, Anhydrides: Part VII—Reductive Cyclisation of 2-Nitromaleanilates & 2-Nitrofumaranilates, a New Synthesis of 2-Oxo-1,2,3,4-tetrahydroquinoxalines”, Indian Journal of Chemistry, Section B: Organic, Incl. Medicinal, Publications and Informations Diectorate, New Delhi, IN, V21B, No. 12, pp. 1071-1073, (1982).
Scoffone E. et al., “Indagini Sulla Struttura Delle Proteine”, Gazzetta Chimica Italiana, Societa Chimica Italiana, Rome, IT, V87, 1957, pp. 354-365.
Menke, et al., “Expression Cloning of a Human B1Bradykinin Receptor”, J. Biol. Chem., 269(34):21583-21586 (1994).
Hess, et al., “Cloning and Pharmacological Characterization of a Human Bradykinin (BK-2) Receptor”, Biochem Biophys. Res. Commun., 184:260-268 (1992).
Ammons, et al., “Effects of Intracardiac Bradykinin on T2-T5Medial Spinothalamic Cells”, The American Physiological Society, 0363-6119, R147-R152 (1985).
Costello, et al., “Suppression of Carageenan-Induced Hyperalgesia, Hyperthermia and Edema by a Bradykinin Antagonist”, European Journal of Pharmacology, 171:259-263 (1989).
Laneuville, et al., “Bradykinin Analogue Blocks Bradykinin-induced Inhibition of a Spinal Nociceptive Reflex in the Rat”, European Journal of Pharmacology, 137:281-285 (1987).
Steranka, et al., “Antinociceptive Effects of Bradykinin Antagonists”, European Journal of Pharmacology, 136:261-262 (1987).
Steranka, et al., “Bradykinin as a Pain Mediator: Receptors are Localized to Sensory Neurons, and Antagonists have Analgesic Actions”, Neurobiology, 85:3245-3249 (1988).
Whalley, et al., “The Effect of Kinin Agonists and Antagonists on the Pain Response of the Human Blister Base”, Naunyn Schmiederberg's Arch. Pharmacol., 336:652-655 (1987).
Back, et al., “Determination of Components of the Kallikrein-Kinin System in the Cerebrospinal Fluid of Patients with Various Diseases”, Res. Clin. Stud. Headaches, 3:219-226 (1972).
Ness, et al., “Visceral Pain: a Review of Experimental Studies”, Pain, 41:167-234 (1990).
Aasen, et al., “Plasma kallikrein Activity and Prekallikrein Levels during Endotoxin Shock in Dogs”, Eur. Surg. Res., 10:50-62(1978).
Aasen, et al., “Plasma Kallikrein-Kinin System in Septicemia”, Arch. Surg., 118:343-346 (1983).
Katori, et al., “Evidence for the Involvement of a Plasma Kallikrein-Kinin System in the Immediate Hypotension Produced by Endotoxin in Anaesthetized Rats”, Br. J. Pharmacol., 98:1383-1391 (1989).
Marceau, et al., “Pharmacology of Kinins: Their Relevance to Tissue Injury and Inflammation”, Gen. Pharmacol., 14:209-229 (1983).
Weipert, et al., “Attenuation of arterial blood pressure fall endotoxin shock in the rat using the competitive bradykinin antagonist Lys-Lys-[Hyp2, Thi5,8, DPhe7]-BK (B4148)”, Brit J. Pharm., 94:282-284 (1988).
Haberland, “The Role of Kininogenases, Kinin Formation and Kininogenase Inhibition in Post Traumatic Shock and Related Conditions”, Klinische Woochen-Schrift, 56:325-331 (1978).
Ellis, et al., “Inhibition of Bradykinin-and Kallikrein-Induced Cerebral Arteriolar Dilation by Specific Bradykinin Antagonist”, Stroke, 18:792-795 (1987).
Kamitani, et al., “Evidence for a Possible Role of the Brain Kallikrein-Kinin System in the Modulation of the Cerebral Circulation”, Circ. Res., 57:545-552 (1985).
Barnes, “Inflammatory Mediator Receptors and Asthma”, Am. Rev. Respir. Dis., 135:S26-S31 (1987).
Burch, et al., “Bradykinin Receptor Antagonists”, Med Res. Reviews., 10::237-269 (1990).
Fuller, et al., “Bradykinin-induced Bronchoconstriction in Humans”, Am. Rev. Respir. Dis., 135:176-180 (1987).
Jin, et al., “Inhibition of Bradykinin-Induced Bronchoconstriction in the Guinea-Pig by a Synthetic B2Receptor Antagonist”, Br. J. Pharmacol., 97:598-602 (1989).
Polosa, et al., “Contribution of Histamine and Prostanoids to Bronchoconstriction Provoked by Inhaled Bradykinin in Atopic Asthma”, Allergy, 45:174-182 (1990).
Baumgarten, et al., “Concentrations of Glandular Kallikrein in Human Nasal Secretions Increase During Experimentally Induced Allergic Rhinitis”, J. Immunology, 137:1323-1328 (1986).
Proud, et al., “Nasal Provocation with Bradykinin Induces Symptoms of Rhinitis and a Sore Throat”, Am. Rev. Respir Dis., 137:613-616 (1988).
Seabrook, et al., “Expression of B1and B2Bradykinin Receptor mRNA and Their Functional Roles in Sympathetic Ganglia and Sensory Dorsal Root Ganglia Neurons from Wild-type and B2Receptor Knockout Mice”, Neuropharmacology, 36(7):1009-17 (1997).
Romanenko et al. “Condensed and bound quinoxalines. IV. New pathway to acrylamides of (1,2-dihydro-2-oxo-3-quinoxalinyl) acetic acid”Khimiya Geterotsiklicheskikh Soedinenii, vol. 2, pp. 264-266 (1973).
De la Losa et al., Bulletin de la Societe Chimique de France, pp. 1621-1625 (1960).
Cunningham and Day, Journal of Organic Chemistry, vol. 38(6), pp. 1225-1227 (1973).
Couture el al, “Kinin receptors in pain and inflammation” European Journal of Pharmacology, vol. 429, pp. 161-176 (2001).
Ozturk, “Kinin Receptors and Their Antagonists as Novel Therapeutic Agents” Current Pharmaceutical Design, vol. 7, pp. 135-161 (2001).
Howl and Payne, “Bradykinin receptors as a therapeutic target” Expert Opinion on Therapeutic Targets, vol. 7(2), pp. 277-2 (2003).
Bartulis Sarah
Brogley Louis
Dappen Michael S.
Grant Francine S.
Hawkinson Jon E.
Elan Pharmaceuticals Inc.
Moore Susanna
Swiss Tanner, P.C.
Wilson James O
LandOfFree
Sulfonylquinoxalone derivatives and related compounds as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sulfonylquinoxalone derivatives and related compounds as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sulfonylquinoxalone derivatives and related compounds as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4110695